Diagnostic tests are generally conducted in public or private laboratories and equipped with proper instrumentation and well-qualified staff for performing tests. Point of Care (POC) testing is dominating the diagnostics market and the scenario is expected to remain unchanged in the years to come. This could be attributed to the convenience factor involved therein. In vitro diagnostics tests could be conducted through reagents, instruments, techniques, or a constellation of these.

Diagnostic imaging devices are witnessing an enormous growth with growing incidences of various chronic injuries and diseases, along with growth of geriatric population. Plus, government bodies are raising the upper limit of funds for boosting awareness regarding importance of diagnostic imaging devices.

These days, biochemistry analyzers are also doing the rounds. Reagents are used for inducing reactions on urine or blood samples for measuring cholesterol, sugar, etc. Early detection is the basic advantage of biochemistry analyzers.

Rapid influenza diagnostics tests are being suggested by the WHO. It is a known fact that influenza epidemics are posing risks to the public health at the global level. Till recently, A/H5N1 avian influenza viruses’ infections have raised the risks of influenza A virus to the extent of turning out to be a pandemic. Of late, commercial influenza rapid diagnostics tests are being made available. Additionally, influenza diagnostics is being driven by surge in seasonal flu.

Diagnostic biomarkers enable early detection of PDA (Patent Ductus Arteriosus). There are predictive markers that provide personalized treatment regimens. Prognostic markers do predict recurrence as well as patient survival patterns. As of now, biomarkers in operation are – creatinine to diagnose renal insufficiency, amylase to diagnose pancreatitis, and troponin level to diagnose myocardial infarction. Extensive research is being conducted to get into the depth of role of biomarkers in neurology.

There are also molecular diagnostics for addressing diseases like cancer and various infectious ailments. Molecular diagnostics are also being deployed to manage the ongoing pandemic (Covid-19). Plus, companion diagnostics are in great demand. It has been observed that co-development of therapeutic products and companion diagnostics could give better/safer drugs with improved therapeutic efficacy and cost-effectiveness.

Moreover, viral molecular diagnostics is picking up pace with growing awareness regarding viral infections. The present scenario is such that advances on the count of biotechnology are addressing the demand for novel vaccines, drugs for several viral infections, ultimately driving the viral molecular diagnostics market.

For hard-core fish consumers, shrimp disease diagnostics need to be pondered about. By type of disease, shrimp disease diagnostics comprise assay based kits (WSSV (White Spot Syndrome Virus)) and rapid testing kits (TSV (Taura Syndrome Virus), THV/GAV (Yellow Head/Gill Associated Virus), IHHNV (Infectious Hypodermal and Hematopoietic Virus), HPV (HEPATOpancreatic Parvovirus), MBV (Monodon Baculovirus), IMNV (Infectious Myonecrosis Virus), NHP-B (Necrotising Hepatopancreatitis Bacteria), MoV (Mourilyan Virus), and EMS (Early Mortality Syndrome)).

Persistence Market Research (PMR) has profiled the key players in “diagnostics market”

• Abbott Laboratories
• Hoffmann-La Roche Ltd.
• Siemens
• Thermo Fisher Scientific Inc.
• Danaher, Bio-Rad Laboratories
• QIAGEN
• Sysmex Corporation
• Quest Diagnostics Inc.

Regarding developments, PMR has mentioned about Sysmex Corp entering into joint venture with JVCKENWOOD Corp. in August 2018 for establishing a new-fangled manufacturing company named “Creative Nanosystems Corp.” for manufacturing and developing bio-devices.

Persistence Market Research (PMR) has also mentioned about the diagnostics market spread geography-wise. It states that out of North America, Europe, the Asia-Pacific, LATAM, and MEA, North America holds the first position in diagnostics market, followed by the Europe. The Asia-Pacific is expected to grow at the fastest rate in the forecast period with key players investing in this market due too affable resources.

Persistence Market Research has segregated the diagnostics market by type of product as reagents & consumables and instruments. Technique-wise, it says molecular diagnostics (as explained above), clinical chemistry, immunodiagnostics, hematology, Point of Care, and others. Application-wise, it’s cardiology, oncology, gastroenterology, and infectious diseases. End-user wise, it’s hospitals, clinical laboratories, physicians’ offices.

Coming to clinical mode of diagnostics, PMR describes the diagnostics market by test as liver panel, lipid panel, renal panel, complete blood count, infectious disease testing, electrolyte testing, and various other tests.

As far as point of care diagnostics is concerned, Persistence Market Research (PMR) says cardiometabolic monitoring products, glucose monitoring products, coagulation monitoring products, infectious disease testing products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, drugs-of-abuse testing products, cholesterol testing products, and various other POC products.